Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

PIONEER 4 investigators

Research output: Contribution to journalArticlepeer-review

114 Scopus citations

Fingerprint

Dive into the research topics of 'Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial'. Together they form a unique fingerprint.

Medicine & Life Sciences